세포 및 유전자 치료 자금조달 및 자본거래 분석 : 자금조달, 제휴, 인수합병(M&A), 기술이전, IPO/SPAC, 기타 거래(2021-2023년)

Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023

US $ 5,000 ￦ 6,984,000

Online Access (Single User License)

PDF 보고서를 1분이 열람(다운로드 불가)할 수 있는 라이선스입니다. 인쇄는 1회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,500 ￦ 10,476,000

Online Access & PDF Download (10 Users)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 인쇄는 10회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,969,000

Online Access & PDF Download (Unlimited Users)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유전자 치료와 세포 치료의 개념은 수십년 전부터 연구되어 왔지만, 초기에는 큰 어려움이 있었습니다. 단계적인 발전을 거쳐 CRISPR과 차세대 염기서열 분석기(NGS)와 같은 실현 가능한 도구가 점차 도입되면서 세포 및 유전자 치료는 매우 활발한 분야로 부상했습니다. 현재 많은 검증된 치료법이 승인된 상태입니다.

기술의 발전으로 인해 업계 진입장벽이 낮아지면서 1,500개 이상의 치료제 및 도구 기업이 이 분야에 뛰어들었습니다.

이 보고서는 2021년 이후 세포 및 유전자 치료(CGT) 거래 활동을 추적하고 있습니다. 2021년부터 2023년까지 분기별 추이를 그래프로 보여주고, 2022년 1분기부터 2023년 3분기까지 2,000건 이상의 자본 거래에 대한 구체적인 내용을 담고 있습니다. 최근 세포 및 유전자 치료(CGT) 관련 분야에 많은 관심과 자금이 집중되고 있습니다. 본 보고서에서 추적한 CGT 투자, 인수 및 기타 거래는 2023년 1분기부터 3분기까지 200억 달러 이상에 달했습니다. 가장 빠르게 성장하는 시장 중 하나인 CGT의 비즈니스 기회를 활용하기 위해서는 어떤 유형의 거래가 얼마나 이루어지고 있는지, 누가 어떤 거래를 얼마나 하고 있는지, 그리고 거래의 세부 사항을 이해하는 것이 중요합니다.

본 보고서의 분석 내용(일부) :

• 분기별 펀딩 금액(2021년-2023년)
• CGT 분야 자본거래 상세 정보(2022-2023년) : 총 2,000건 이상
• 벤처캐피털(JV)/민간자금 유치 건수(분기별)
• 여러 카테고리(VC, M&A, 기타 분야)로 구분하여 시계열로 트렌드를 소개합니다.
• 유형별 자본거래 동향 : 기술/연구/전략적 제휴, 벤처캐피탈/민간투자, 인수합병(M&A)/전략적 투자, 라이선스 계약, 기업공개/스팩(SPAC), 제조/공급망, 공공지원/자선활동, 교육, 유통, 공동마케팅, 스핀아웃, 구조조정, 거래 완료/종료, 합작투자, 소송 합의
• 자본거래가 가장 활발한 기업(딜 유형별(인수합병(M&A), 전략적 투자, 종합적 거래, 제휴))
• 자본거래 지역별 분석(%, 북미, 유럽, 아시아태평양, 기타 지역)
• 가장 빈번하게 이루어진 자본조달 유형(분기별, 카테고리별)(기술/연구/전략적 협업, 벤처캐피탈/민간투자, 인수합병(M&A)/전략적 투자, 라이선스 계약, IPO/SPAC, 제조/공급망)(총 합계)

세포 및 유전자 치료는 매우 경쟁이 치열한 시장이기 때문에 본 보고서에서는 1,000개 이상의 기업을 구체적으로 언급하고 있습니다.

목차

제1장 주요 요약

• 서론
• 2023년 최초 9개월 사이에 271억 달러 투자
• 분기별 자금조달 액스
• 분기별 자금조달 액수 : 카테고리별 점유율(2021년 1분기-2023년 3분기)
• 분기별 거래 건수 : 카테고리별(2021년 1분기-2023년 3분기)
• 협업 및 제조/공급망 거래, 라이선스 계약, 유통/공동 마케팅 확대가 세포 및 유전자 치료 활동을 강조
• 빈도가 낮은 CGT 거래 유형 개요
• 가장 활발한 기업

제2장 벤처캐피털(VC)과 민간 자금

• 유동적인 VC/민간 자금

제3장 전략적 투자

• 세포 및 유전자 치료에 대한 전략적 투자

제4장 IPO·FPO·SPAC

• 북미에서는 매출의 대부분이 IPO·FPO·SPAC에서 발생

제5장 인수합병(M&A)

• 평균 금액은 감소했지만, M&A 건수는 증가

제6장 기술/조사/전략 협업

• CGT 시장에서는 폭넓은 협업을 볼 수 있다

제7장 라이선스 계약

• 세포 및 유전자 치료 시장의 라이선스 계약은 안정적인 수준

제8장 제조 및 공급망

• CGT 제조 및 공급망 관리 활동의 대폭적인 성장

제9장 공적 지원 및 교육, 자선 활동

• CGT 시장은 공적 지원, 환자/소비자/연수생 교육, 자선 활동에 별로 초점을 맞추지 않았다.

제10장 유통 및 공동 마케팅

• CGT 유통 및 공동 마케팅 거래 개요

제11장 기타 : JV, 재편, 해산, 스핀오프

• 세포 및 유전자 치료에 영향을 미치는 기타 유형의 거래 개요

LSH

영문 목차

영문목차

While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved therapies with proven track records.

As the technologies have lowered the barriers to entry for the industry, over 1,500 therapy or tools companies have been created or have become involved in this field.

This report, Kalorama's “Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023”, tracks the dealmaking activities in cell and gene therapy since 2021. The report provides informative graphs of quarterly trends from 2021-2023, and also includes the specific details of over 2,000 deals covering the Q1 2022-Q3 2023 period. A lot of attention and funding is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's tracked CGT investments, acquisitions, and other deals amounted to more than $20 billion in the first three quarters of 2023. Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.

Kalorama's report is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

The following is just some of the information in this report:

• Quarterly Funding Amounts 2021-2023

• Specific details of 2000+ CGT Deals from 2022-2023

• Venture Capital/Private Funding Round Amounts, By Quarter

• Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)

• Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation

• Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)

• Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

• Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)

No report published by a major market research publisher has tackled the current Cell and Gene Therapy dealmaking space more comprehensively.

There isn't a more comprehensive exploration of the current Cell and Gene Therapy dealmaking landscape by any major market research publisher. As Cell and Gene Therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.

Table of Contents

Chapter 1: Executive Summary

• Introduction
• $27.1 Billion in Investment in First Nine Months of 2023
  • Figure 1-1: Total Deals per Month, Apr 2021-Sep 2023 (count)
  • Figure 1-2: Total Deals per Month by Type, Apr 2021-Sep 2023 [VC/Private, IPO/FPO/SPAC; and All Other Deals] (count)
• Quarterly Funding Amounts
  • Table 1-1: Total Quarterly Funding, by Type, Q1-Q3 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Table 1-2: Total Quarterly Funding, by Type, 2022 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Table 1-3: Total Quarterly Funding, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Figure 1-3: Total Quarterly Funding, Q1 2021- Q3 2023 ($M)
  • Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q3 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
• Quarterly Funding Category Shares, Q1 2021 Through Q3 2023
  • Table 1-4: Total Quarterly Funding Share, by Type, 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Table 1-5: Total Quarterly Funding Share, by Type, 2022 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Table 1-6: Total Quarterly Funding Share, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Figure 1-5: Total Quarterly Funding Share, by Type, Q1 2021-Q3 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-6: 2021 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-7: 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-8: 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
• Quarterly Deal Counts by Category, Q1 2021 - Q3 2023
  • Table 1-7: Quarterly Count of Deals, By 2023 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
  • Table 1-8: Quarterly Count of Deals, by 2022 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
  • Table 1-9: Quarterly Count of Deals, by 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
  • Table 1-10: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation], 2021-2023 partial (%)
• Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
  • Figure 1-9: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation], 2021-2023 partial (%)
  • Figure 1-10: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain], 2021-2023 partial (Total number)
• A Look at Less Frequent CGT Deal Types
  • Figure 1-11: Lower Frequency Deal Types, by Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
  • Figure 1-12: Merger/ Acquisition Amount, by Quarter [Q1 2021 - Q3 2023] ($M)
  • Figure 1-13: Venture Capital/Private Funding Round Amount, by Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 1-14: IPO/FPO Amount, by Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 1-15: SPAC Portion Amount, by Year 2021-2023 ($M)
• Most Active Companies
  • Table 1-11: Most Active Companies in CGT Deals, Collaborations, Overall 2021-2023
  • Figure 1-16: Most Active Companies in CGT Deals, Collaborations, Overall 2021-2023

Chapter 2: Venture Capital & Private Funding

• VC/Private Funding in Flux
• Figure 2-1: Total Number of VC/Private Funding Deals by Month, Jan 2021-Sep 2023 (count)
  • Figure 2-2: Average VC/Private Funding Round Amount, by Quarter Q1 2021- Q1 2023 ($M)
  • Table 2-1: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q3 2023, by Region[North America, Europe, APAC, Rest of World] ($M) (%)
  • Figure 2-3: Quarterly Venture Capital/Private Total Funding, Q1 2021- Q1 2023, by Region [North America, Europe, APAC, Rest of World] ($M)
  • Table 2-2: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q3 2023, [North America, Europe, APAC, Rest of World] (%)
  • Figure 2-4: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q3 2023, by Region [North America, Europe, APAC, Rest of World] (%)
  • Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q3 2023] ($M)
  • Table 2-3: Venture Capital/Private Fundraising Deals, Q3 2023
  • Table 2-4: Venture Capital/Private Fundraising Deals, Q2 2023
  • Table 2-5: Venture Capital/Private Fundraising Deals, Q1 2023
  • Table 2-6: Venture Capital/Private Fundraising Deals, Q4 2022
  • Table 2-7: Venture Capital/Private, Q3 2022
  • Table 2-8: Venture Capital/Private Fundraising Deals, Q2 2022
  • Table 2-9: Venture Capital/Private Fundraising Deals, Q1 2022

Chapter 3: Strategic Investments

• Strategic Investments in Cell and Gene Therapy
  • Figure 3-1: Total Number of Strategic Investments, By Quarter [Q1 2021-Q3 2023] (count)
  • Figure 3-2: Average Strategic Investment Amount, By Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 3-3: Total Strategic Investments, By Quarter [Q1 2021-Q3 2023] ($M)
  • Table 3-1: Strategic Investment Total Amounts, Counts, and Averages by Quarter, Q1 2021-Q3 2023, ($M)
  • Table 3-2: Strategic Investments, January 2021-September 2023
  • Table 3-3: Most Active in Acquisition/Merger/Strategic Investment, 2021-2023
  • Figure 3-4: Most Active in Acquisition/Merger/ Strategic Investment, 2021-2023

Chapter 4: IPOs, FPOs, & SPACs

• North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
  • Figure 4-1: Total Number of IPOs/ FPOs, By Month [Jan 2021-Sep 2023] (count)
  • Figure 4-2: Average IPO/FPO Proceeds, By Quarter [Q1 2021-Q3 2023] ($M)
  • Table 4-1: Quarterly IPO/FPO Total Funding, Q1 2021-Q3 2023, by Region [North America, Europe, APAC] ($M)
  • Figure 4-3: Total IPO/FPO Funding, By Quarter [Q1 2021-Q3 2023], by Region [North America, Europe, APAC] ($M)
  • Table 4-2: Regional IPO/FPO Funding Shares, by Quarter, Q1 2021-Q3 2023, by Region [North America, Europe, APAC] (%)
  • Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021-Q3 2023, by Region [North America, APAC, and Europe) (%)
  • Figure 4-5: IPO/FPO Amounts, By Quarter [Q1 2021-Q3 2023] ($M)
  • Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q3 2023 ($M)
  • Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q3 2023 ($M)
  • Table 4-4: IPO/FPO Deals, Q3 2023
  • Table 4-5: IPO/FPO Deals, Q2 2023
  • Table 4-6: IPO/FPO Deals, Q1 2023
  • Table 4-7: IPO/FPO Deals, Q4 2022
  • Table 4-8: IPO/FPO Deals, Q3 2022
  • Table 4-9: IPO/FPO Deals, Q2 2022
  • Table 4-10: IPO/FPO Deals, Q1 2022
  • Table 4-11: SPAC Portion, January 2021-September 2023 ($M)
  • Figure 4-7: SPAC Portion Amount, by Year, 2021-2023 ($M)

Chapter 5: Mergers & Acquisitions (M&A)

• Growing Numbers of M&A, Despite Lower Average Value
  • Figure 5-1: Total Number of Mergers and Acquisitions, By Month [Jan 2021-Sep 2023] (count)
  • Figure 5-2: Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q3 2023] ($M)
  • Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q3 2023 ($M) (Total count)
  • Figure 5-3: Merger/Acquisition Transactions Global Total, By Quarter [Q1 2022- Q3 2023] ($M)
  • Figure 5-4: Merger/Acquisition Amounts, by Quarter [Q1 2021-Q3 2023] ($M)
  • Table 5-2: Mergers and Acquisitions Announcements, Q3 2023 ($M)
  • Table 5-3: Mergers and Acquisitions Announcements, Q2 2023 ($M)
  • Table 5-4: Mergers and Acquisitions Announcements, Q1 2023 ($M)
  • Table 5-5: Mergers and Acquisitions, Q4 2022 ($M)
  • Table 5-6: Mergers and Acquisitions, Q3 2022 ($M)
  • Table 5-7: Mergers and Acquisitions, Q2 2022 ($M)
  • Table 5-8: Mergers and Acquisitions, Q1 2022 ($M)
  • Table 5-9: Most Active in Acquisition/Merger/Strategic Investment, 2021-2023 (count)
  • Figure 5-5: Most Active in Acquisition/Merger/Strategic Investment, 2021-2023

Chapter 6: Technology/Research/Strategic Collaborations

• CGT Market Sees a Broad Variety of Collaborations
  • Figure 6-1: Total Number of Tech/Research/Strategic Collaborations, By Month [Jan 2021-Sep 2023] (count)
  • Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter [Q1 2021-Q3 2023] ($M)
  • Table 6-1: Collaboration Upfront and Future/Milestone Payments, Counts, Averages, Q1 2021-Q3 2023 ($M) (count)
  • Figure 6-3: Average Collaboration Upfront Payment, By Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 6-4: Research Collaboration Upfront Payments, By Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 6-5: Average Collaboration Future/Milestone Payments, By Quarter [Q1 2021-Q3 2023] ($M)
  • Figure 6-6: Total Collaboration Future/Milestone Payments, By Quarter [Q2 2021-Q3 2023] ($M)
  • Table 6-2: Technology/Research/Strategic Collaboration Deals, Q3 2023
  • Table 6-3: Technology/Research/Strategic Collaboration Deals, Q2 2023
  • Table 6-4: Technology/Research/Strategic Collaboration Deals, Q1 2022-Q3 2023
  • Table 6-5: Most Active in Research/Strategic Collaborations, 2021-2023 (count)
  • Figure 6-7: Most Active in Research/Strategic Collaborations, 2021-2023 (count)

Chapter 7: Licensing

• Stable Levels of Licensing in the Cell and Gene Therapy Market
  • Figure 7-1: Total Number of Licensing Deals, By Month [Jan 2021-Sep 2023] (count)
  • Table 7-1: Licensing Deals, Q3 2023
  • Table 7-2: Licensing Deals, Q2 2023
  • Table 7-3: Licensing Deals, Q1 2022-Q1 2023
  • Table 7-4: Most Active Companies in Licensing Deals, 2021-2023 (count)
  • Figure 7-2: Most Active Companies in Licensing Deals, 2021-2023 (count)

Chapter 8: Manufacturing and Supply Chain

• Major Growth in Manufacturing and Supply Chain Management Activity in CGT
  • Figure 8-1: Total Number of Supply/ Manufacturing Deals, By Month [Jan 2021-Sep 2023] (count)
  • Table 8-1: Manufacturing and Supply Chain Deals, Q3 2023
  • Table 8-2: Manufacturing and Supply Chain Deals, Q2 2023
  • Table 8-3: Manufacturing and Supply Chain Deals, Q1 2022-Q3 2023
  • Table 8-4: Most Active Companies in Manufacturing/ Supply Deals, 2021-2023 (count)
  • Figure 8-2: Most Active Companies in Manufacturing/ Supply Deals, 2021-2023 (count)

Chapter 9: Public Outreach, Education, & Philanthropy

• CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy
  • Figure 9-1: Total Number of Outreach/ Philanthropy/ Education Deals, By Month [Jan 2021-Sep 2023] (count)
  • Table 9-1: Outreach, Education, & Philanthropy Deals, January 2022-Aug 2023

Chapter 10: Distribution & Co-Marketing

• A Look at CGT Distribution and Co-Marketing Deals
  • Figure 10-1: Total Number of Distribution/ Co-Marketing Deals, by Month [Jan 2021-Sep 2023] (count)
  • Table 10-1: Distribution & Co-Marketing Deals, Q3 2023
  • Table 10-2: Distribution & Co-Marketing Deals, Q2 2023
  • Table 10-3: Distribution & Co-Marketing Deals, Q1 2022-Q1 2023

Chapter 11: Other - JV, Restructuring, Termination, Spinoffs

• A Look at Other Types of Deals Impacting Cell and Gene Therapy
  • Figure 11-1: Total Number of JV, Restructuring, Termination, By Month [Jan 2021-Sep 2023] (Total count)
  • Table 11-1: Restructuring, JV, Termination, Spinoffs, January 2022-Sep 2023

관련자료